Intravenous immunoglobulin for myasthenia gravis

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2008, Pages

  Gajdos, Philippe ^a   Chevret, S ^b   Toyka, K ^b  

^a RAYMOND POINCARÉ HOSPITAL   (France)

^b NONE

Author keywords

Humans; Immunoglobulins, intravenous *therapeutic use ; Myasthenia gravis *therapy ; Plasma exchange; Randomized controlled trials as topic

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID DERIVATIVE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; PLACEBO; PREDNISONE;

AGITATION; CHILL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CREATININE BLOOD LEVEL; DATA EXTRACTION; DEEP VEIN THROMBOSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FEVER; HEADACHE; HEMATOMA; HEMOLYSIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOTENSION; MYASTHENIA GRAVIS; NAUSEA; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PLASMAPHERESIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEPTICEMIA; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TACHYCARDIA; VEIN THROMBOSIS; VOMITING;

EID: 44949201207     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD002277.pub3     Document Type: Review

References (46)

1. Gajdos 1997 {published data only} *Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high dose immunoglobulin in myasthenia gravis. Annals of Neurology 1997;41(6):789-96. [MEDLINE: 97332878].
2. Gajdos 2005 {published data only} Gajdos P, Tranchant C, Clair B, Bolgert F, Eymard B, Stojkovic T, et al.Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin 1g/kg versus 2g/kg: a randomized double blind clinical trial. Archives of Neurology 2005; Vol. 62, issue 11:1689-93.
3. Ronager 2001 {published data only} *Ronager J, Ravnborg M, Hermansen I, Vorstrup S. Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. Artificial Organs 2001;25(12):967-73. [MEDLINE: 21832716].
4. Schuchardt 2002 {unpublished data only} Schuchardt V, Kohler W, Hund E, Scheglmann K, Fleisher E, Jung K, et al.A randomized controlled trial of high dose intravenous immunoglobulin versus methylprednisolone in myasthenia gravis. An interim analysis. 2002. Data on file.
5. Wolfe 2002 {unpublished data only} *Wolfe GI, Barohn RJ, Foster BM, Jackson CE, Kissel JT, Day JW, et al.Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis. Muscle & Nerve 2002;26(4):549-52. [MEDLINE: 22249302].
6. Zinman 2007 {published data only} Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis. A randomized controlled trial. Neurology 2007;68(11): 837-41.
7. Achiron 2000 Achiron A, Barak Y, Miron S, Sarova-Pinas I. Immunoglobulin treatment in refractory myasthenia gravis. Muscle & Nerve 2000;23(4): 551-5. [MEDLINE: 20181951].
8. Arsura 1986 Arsura EL, Bick A, Brunner NG, Namba T, Grob D. High dose intravenous immunoglobulin in the management of myasthenia gravis. Archives of Internal Medicine 1986;146(7):1365-8. [MEDLINE: 86241223].
9. Arsura 1988 Arsura EL, Bick A, Brunner NG, Grob D. Effect of repeated doses of intravenous immunoglobulin in myasthenia gravis. American Journal of the Medical Sciences 1988;295(5):438-43. [MEDLINE: 88238634].
10. Arsura 1989 Arsura EL. Experience with intravenous immunoglobulin in myasthenia gravis. Clinical Immunology and Immunopathology 1989;53(2 Pt 2):S170-9. [MEDLINE: 90003918].
11. Besinger 1983 Besinger UA, Toyka KV, Homberg M, Heininger K, Hohlfeld R, Fateh-Moghadam A. Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology 1983;33(10): 1316-21. [MEDLINE: 83298072].
12. Blanchette 1994 Blanchette V, Imbach P, Andrew M, Adams M, McMillan J, Wang E, et al.Randomised trial of intravenous immunoglobulin G, intravenous anti-D and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet 1994;344(8924):703-7. [MEDLINE: 94359310].
13. Buchwald 2002 Buchwald B, Ahangari R, Weishaupt A, Toyka KV. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barre syndrome. Annals of Neurology 2002;51(6):673-80. [MEDLINE: 22104994].
14. Buchwald 2005 Buchwald B, Ahangari R, Weishaupt A, Toyka KV. Presynaptic effects of immunoglobulin G from patients with Lambert-Eaton myasthenic syndrome: their neutralization by intravenous immunoglobulins. Muscle & Nerve 2005;31(4):487-94.
15. Cosi 1991 Cosi V, Lombardi M, Piccolo G, Erbetta A. Treatment of myasthenia gravis with high dose intravenous immunoglobulin. Acta Neurologica Scandinavica 1991;84(2):81-4. [MEDLINE: 92057584].
16. Dalakas 1993 Dalakas MC, Illa I, Dambrosia JM, Souiedan SA, Stein DP, Otero C, et al.A controlled trial of high dose intravenous immune globulin infusions as treatment for dermatomyositis. New England Journal of Medicine 1993;329(27):1993-2000. [MEDLINE: 94067261].
17. Dalakas 1999 Dalakas MC. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle & Nerve 1999;22(11):1479-97. [MEDLINE: 99443971].
18. Dau 1977 Dau PC, Lindstrom JM, Cassel CK, Denys EH, Shev EE, Spitler LE. Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis. New England Journal of Medicine 1977;297(21):1134-40. [MEDLINE: 78031083].
19. Dwyer 1992 Dwyer JM. Manipulating the immune system with immune globulin. New England Journal of Medicine 1992;326(2):107-16. [MEDLINE: 92079982].
20. Evoli 1993 Evoli A, Palmisani M.T, Bartoccioni E, Padua L, Tonali P. High dose intravenous immunoglobulin in myasthenia gravis. Italian Journal of Neurological Sciences 1993;14(3):233-7. [MEDLINE: 93300635].
21. Fateh-Moghadam 1984 Fateh-Moghadam A, Wick M, Besinger U, Geursen RG. High dose intravenous gammaglobulin for myasthenia gravis. Lancet 1984;1 (8381):848-9. [MEDLINE: 84166915].
22. Gajdos 1983 Gajdos P, Simon N, de Rohan-Chabot P, Raphael JC, Goulon M. Long term effects of plasma exchange in myasthenia gravis. Results from a randomised study [Effet à long terme des échanges plasmatiques au cours de la myasthénie. Résultats d'une étude randomisée]. Presse Médicale 1983;12(15):939-42. [MEDLINE: 83194859].
23. Gajdos 1984 Gajdos P, Outin HD, Elkharrat D, Brunel D, de Rohan-Chabot P, Raphaël JC, et al.High dose intravenous gammaglobulin for myasthenia gravis. Lancet 1984;1(8373):406-7. [MEDLINE: 84116444].
24. Gajdos 1987 Gajdos P, Outin HD, Morel E, Raphaël JC, Goulon M. High dose intravenous gamma globulin for myasthenia gravis: an alternative to plasma exchange. Annals of the New York Academy of Sciences 1987; 505:842-44.
25. Gajdos 2002 Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database of Systematic Reviews 2002, Issue 4.Art. No.: CD002275. DOI:10.1002/14651858.CD002275.
26. Godeau 1993 Godeau B, Lesage S, Divine M, Wirquin V, Farcet JP, Bierling P. Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high dose intravenous immunoglobulin. Blood 1993; 82(5):1415-21. [MEDLINE: 93372336].
27. Hilkevich 2001 Hilkevich O, Drory VE, Chapman J, Korczyn AD. The use of intravenous immunoglobulin as maintenance therapy in myasthenia gravis. Clinical Neurophamacology 2001;24(3):173-6. [MEDLINE: 21285976].
28. Hohlfeld 1996 Hohlfeld R, Melms A, Toyka KV, Drachman DB. [Therapy for myasthenia gravis]. Neurological disorders: course and treatment. San Diego, CA: Academic Press, 1996:947-64.
29. Imbach 1981 Imbach P, Barandun S, d'Apuzzo V, Baumgartner C, Hirt A, Morell A, et al.High dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981;1(8232):1228- 31. [MEDLINE: 81196405].
30. Jaretzki 2000 Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, et al.Myasthenia gravis: recommendations for clinical research standards. Neurology 2000;55(1):16-23. [MEDLINE: 20351615].
31. Kornfeld 1981 Kornfeld P, Ambinder EP, Mittag T, Bender AN, Papatestas AE, Goldberg J, et al.Plasmapheresis in refractory generalized myasthenia gravis. Archives of Neurology 1981;38(8):478-81. [MEDLINE: 81231815].
32. McConville 2004 McConville J, Farrugia ME, Beeson D, Kishore U, Metcalfe R, Newsom-Davis J, et al.Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Annals of Neurology 2004;55(4):580-4.
33. Newsom-Davis 1979 Newsom-Davis J, Wilson SG, Vincent A, Ward CD. Long term effects of repeated plasma exchange in myasthenia gravis. Lancet 1979; 1(8114):464-8. [MEDLINE: 79133792].
34. NIH Consensus 1986 NIH Consensus Conference. The utility of therapeutic plasmapheresis for neurological disorders. The Journal of the American Medical Association 1986;256(10):1333-7. [MEDLINE: 86308305].
35. NIH Consensus 1990 NIH Consensus Conference. Intravenous immunoglobulin: prevention and treatment of disease. The Journal of the American Medical Association 1990;264(24):3189-93. [MEDLINE: 91073585].
36. Oosterhuis 1983 Oosterhuis H.J.G.H, Limburg P.C, Hummel-Tappel E, The T.H. Anti-acetylcholine receptor antibodies in myasthenia gravis: Part 2. Clinical and serological follow-up of individual patients. Journal of the Neurological Sciences 1983;58(3):371-85.
37. Osserman 1971 Osserman K.E, Genkins G. Studies in myasthenia gravis: review of a twenty year experience in over 1200 patients. The Mount Sinai Journal of Medicine 1971;38(6):497-537.
38. Perez-Nellar 2001 Perez-Nellar J, Dominguez AM, Llorens-Figueroa JA, Ferra-Betancourt A, Pardo A, Quiala M, et al.A comparative study of intravenous immunoglobulin and plasmapheresis preoperatively in myasthenia [Estudio comparativo entre immunoglobulina intravenosa y plasmaferesis en el perioperatorio de la miastenia gravis]. Revista de Neurologia 2001;33(5):413-6.
39. Pinching 1976 Pinching AJ, Peters DK. Remission of myasthenia gravis following plasma exchange. Lancet 1976;2(8000):1373-6. [MEDLINE: 77076050].
40. PSGBS Group 1997 Plasma exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997;349(9047):225-30. [MEDLINE: 97167219].
41. Qureshi 1999 Qureshi AI, Choudhry MA, Akbar MS, Mohammad Y, Chua HC, Yahia AM, et al.Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology 1999;52(3):629-32. [MEDLINE: 99148668].
42. Rodnitzky 1984 Rodnitzky RL, Bosch EP. Chronic long interval plasma exchange in myasthenia gravis. Archives of Neurology 1984;41(7):715-7. [MEDLINE: 84256137].
43. Sharshar 2000 Sharshar T, Chevret S, Mazighi M, Chillet P, Huberfeld G, Berreotta C, et al.Validity and reliability of two muscle strength scores commonly used as endpoints in assessing treatment of myasthenia gravis. Journal of Neurology 2000;247(4):286-90. [MEDLINE: 20294610].
44. Tindall 1987 Tindall RSA, Rollins JT, Phillips, Greenlee RG, Wells L, Belendiuk G, et al.Preliminary results of a double blind, randomized, placebo controlled trial of cyclosporine in myasthenia gravis. New England Journal of Medicine 1987;316(12):719-724.
45. Van der Meché 1997 Van der Meché FG, Van Doorn PA. The current place of high-dose immunoglobulins in the treatment of neuromuscular disorders. Muscle & Nerve 1997;20(2):136-47. [MEDLINE: 97193058].
46. Vincent 2003 Vincent A, Bowen J, Newsom-Davis J, McConville J. Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets. Lancet Neurology 2003;2(2):99-106.